
  
    
      
        Background_NNP
        At_IN least_JJS one_CD third_NN of_IN the_DT 48_CD human_JJ members_NNS of_IN the_DT
        nuclear_JJ hormone_NN receptor_NN superfamily_RB function_NN as_IN
        heterodimers_NNS with_IN the_DT Retinoid_NNP X_NNP Receptors_NNP ,_, (_( RXRs_NNP ,_, NR_NNP 2_CD B_NNP 1_CD -_: 3_LS )_)
        [_NN 1_CD ]_NN ._. Some_DT ,_, but_CC not_RB all_DT of_IN these_DT heterodimers_NNS can_MD be_VB
        directly_RB activated_VBN by_IN RXR_NNP agonists_NNS ,_, called_VBN rexinoids_NNS ,_, which_WDT
        include_VBP the_DT endogenous_JJ ligand_NN 9_CD -_: cis-retinoic_JJ acid_NN
        (_( 9_CD -_: cis-_NN RA_NNP )_) and_CC a_DT number_NN of_IN synthetic_JJ compounds_NNS ._. The_DT
        rexinoid_NN responsive_JJ complexes_NNS are_VBP referred_VBN to_TO as_IN permissive_JJ
        and_CC include_VBP the_DT Peroxisome_NNP Proliferator_NNP Activated_NNP Receptor_NNP
        (_( PPAR_NNP )_) and_CC the_DT Farnesoid_NNP X_NNP Receptor_NNP (_( FXR_NNP )_) heterodimers_NNS ;_: the_DT
        Retinoic_NNP Acid_NNP Receptor_NNP (_( RAR_NNP )_) ,_, and_CC Thyroid_NNP Hormone_NNP Receptor_NNP
        (_( TR_NNP )_) heterodimers_NNS are_VBP non-permissive_JJ [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ._.
        The_DT xenobiotic_JJ receptor_NN CAR_NNP (_( NR_NNP 1_CD I_PRP 3_LS )_) [_NN 8_CD 9_CD ]_NN is_VBZ one_CD of_IN
        several_JJ RXR_NNP heterodimers_NNS that_WDT has_VBZ not_RB been_VBN assigned_VBN to_TO
        either_CC category_NN ._. Initial_JJ results_NNS showed_VBD that_IN CAR_NNP is_VBZ an_DT
        apparently_RB constitutive_JJ transactivator_NN able_JJ to_TO activate_VBP
        gene_NN expression_NN in_IN the_DT absence_NN of_IN exogenously_RB added_VBD ligands_NNS
        [_NN 8_CD 9_CD ]_NN ._. The_DT first_JJ CAR_NNP ligands_NNS identified_VBN ,_, androstanol_NN and_CC
        androstenol_NN ,_, are_VBP inverse_NN agonists_NNS that_WDT block_VBP this_DT
        constitutive_JJ transactivation_NN [_NN 10_CD ]_NN ._. More_RBR recently_RB ,_, it_PRP has_VBZ
        been_VBN found_VBN that_IN CAR_NNP mediates_NNS the_DT characteristic_JJ response_NN of_IN
        a_DT subset_NN of_IN drug_NN metabolizing_VBG enzymes_NNS to_TO a_DT variety_NN of_IN
        structurally_RB unrelated_JJ foreign_JJ compounds_NNS [_NN 11_CD ]_NN ._. These_DT
        xenobiotic_JJ activators_NNS are_VBP referred_VBN to_TO as_IN "_'' phenobarbital_NN
        (_( PB_NNP )_) -_: like_IN ,_, "_'' based_VBN on_IN the_DT prototypic_JJ effects_NNS of_IN the_DT
        anti-epileptic_JJ agent_NN on_IN drug_NN metabolism_NN [_NN 12_CD 13_CD 14_CD ]_NN ._. The_DT
        most_RBS potent_JJ activator_NN of_IN murine_NN CAR_NNP is_VBZ the_DT high_JJ affinity_NN
        agonist_NN ligand_NN TCPOBOP_NNP (_( 1_CD ,_, 4_CD -_: bis_NNS
        [_NN 2_CD -_: (_( 3_CD ,_, 5_CD -_: dichloropyridyloxy_NN )_) ]_NN benzene_NN )_) [_NN 15_CD 16_CD ]_NN ._.
        The_DT effects_NNS of_IN specific_JJ RXR_NNP ligands_NNS on_IN the_DT CAR_NNP /_NN RXR_NNP
        heterodimer_NN have_VBP not_RB been_VBN characterized_VBN ,_, although_IN high_JJ
        concentrations_NNS of_IN both_DT 9_CD -_: cis-_NN RA_NNP and_CC all-trans_JJ retinoic_JJ acid_NN
        have_VBP been_VBN reported_VBN to_TO block_VB PB_NNP induction_NN of_IN the_DT CAR_NNP targets_NNS
        CYP_NNP 2_CD B_NNP 1_CD and_CC CYP_NNP 2_CD B_NNP 2_CD in_IN primary_JJ rat_NN hepatocytes_NNS [_NN 17_CD ]_NN ._. In_IN
        addition_NN ,_, a_DT recent_JJ report_NN suggests_VBZ that_IN both_DT compounds_NNS
        decrease_VBP TCPOBOP-dependent_NNP CAR_NNP transactivation_NN [_NN 18_CD ]_NN ._. In_IN
        both_DT cases_NNS ,_, these_DT effects_NNS were_VBD primarily_RB attributed_VBN to_TO
        sequestration_NN of_IN limiting_VBG amounts_NNS of_IN RXR_NNP into_IN
        ligand-dependent_JJ homodimers_NNS or_CC heterodimers_NNS with_IN other_JJ
        receptors_NNS ._.
        We_PRP have_VBP used_VBN several_JJ approaches_NNS to_TO specifically_RB examine_VB
        the_DT responsiveness_NNS of_IN the_DT CAR_NNP /_NN RXR_NNP heterodimer_NN to_TO rexinoids_NNS ._.
        Unexpectedly_NNP ,_, different_JJ responses_NNS were_VBD observed_VBN using_VBG
        different_JJ methods_NNS ._. Direct_NNP biochemical_JJ measurements_NNS
        demonstrate_VBP that_IN rexinoids_NNS can_MD induce_VB coactivator_NN binding_JJ ,_,
        but_CC can_MD also_RB inhibit_VB the_DT effects_NNS of_IN CAR_NNP agonist_NN and_CC inverse_NN
        agonist_NN ligands_NNS ._. In_IN transient_JJ transfections_NNS ,_, the_DT presence_NN
        of_IN RXR_NNP ligands_NNS can_MD also_RB inhibit_VB the_DT effects_NNS of_IN these_DT CAR_NNP
        ligands_NNS ._. However_RB ,_, different_JJ CAR_NNP /_NN RXR_NNP heterodimer_NN binding_JJ
        sites_NNS show_VBP distinct_JJ responses_NNS to_TO RXR_NNP activation_NN ._. Overall_RB ,_,
        these_DT results_NNS significantly_RB increase_VBP the_DT potential_JJ
        complexity_NN of_IN the_DT response_NN of_IN RXR_NNP heterodimers_NNS to_TO RXR_NNP
        ligands_NNS and_CC suggest_VBP a_DT potential_JJ modulatory_NN effect_NN of_IN
        rexinoids_NNS on_IN xenobiotic_JJ responses_NNS ._.
      
      
        Results_NNS
        
          RXR_NNP ligands_NNS block_VBP effects_NNS of_IN CAR_NNP agonist_NN and_CC
          inverse_NN agonist_NN ligands_NNS on_IN coactivator_NN binding_JJ in_IN
          vitro_NN
          Initial_JJ functional_JJ results_NNS suggested_VBD that_DT
          transactivation_NN by_IN CAR_NNP /_NN RXR_NNP heterodimers_NNS is_VBZ not_RB affected_VBN
          by_IN RXR_NNP ligands_NNS ,_, including_VBG 9_CD -_: cis-_NN RA_NNP or_CC synthetic_JJ
          rexinoids_NNS ,_, indicating_VBG that_IN CAR_NNP is_VBZ a_DT non-permissive_JJ RXR_NNP
          partner_NN ._. However_RB ,_, gel_NN shift_NN studies_NNS indicated_VBD that_IN the_DT
          mobility_NN of_IN the_DT CAR_NNP /_NN RXR_NNP complex_JJ bound_VBN to_TO a_DT DR-_NNP 5_CD element_NN
          is_VBZ increased_VBN by_IN the_DT presence_NN of_IN 9_CD -_: cis_NNS RA_NNP ,_, suggesting_VBG that_IN
          the_DT RXR_NNP ligand_NN can_MD bind_NN to_TO the_DT CAR_NNP /_NN RXR_NNP heterodimer_NN ._. An_DT
          increase_NN in_IN the_DT mobility_NN of_IN the_DT CAR_NNP /_NN RXR_NNP complex_NN was_VBD also_RB
          observed_VBN in_IN the_DT presence_NN of_IN TCPOBOP_NNP or_CC androstanol_NN ,_, alone_RB
          or_CC in_IN combination_NN with_IN 9_CD -_: cis_NNS RA_NNP (_( data_NNS not_RB shown_VBN )_) ._.
          To_TO test_VB the_DT effects_NNS of_IN rexinoids_NNS on_IN coactivator_NN
          binding_VBG in_IN a_DT defined_VBN biochemical_JJ system_NN ,_, surface_NN plasmon_NN
          resonance_NN was_VBD used_VBN to_TO characterize_VB the_DT effects_NNS of_IN the_DT
          various_JJ ligands_NNS on_IN binding_JJ of_IN CAR_NNP ,_, RXR_NNP and_CC CAR_NNP /_NN RXR_NNP
          heterodimers_NNS to_TO SRC-_NNP 3_CD (_( also_RB known_VBN as_IN ACTR_NNP ,_, p_NN /_NN CIP_NNP ,_, RAC_NNP 3_CD ,_,
          AIB_NNP 1_CD ,_, TRAM-_NNP 1_LS )_) ,_, an_DT effective_JJ coactivator_NN for_IN CAR_NNP and_CC many_JJ
          other_JJ members_NNS of_IN the_DT nuclear_JJ receptor_NN superfamily_RB ._. As_IN
          expected_VBN ,_, 9_CD -_: cis-_NN RA_NNP stimulated_VBN coactivator_NN binding_JJ to_TO RXR_NNP
          alone_RB ,_, and_CC the_DT basal_NN interaction_NN of_IN CAR_NNP with_IN SRC-_NNP 3_CD was_VBD
          enhanced_VBN by_IN TCPOBOP_NNP and_CC decreased_VBN by_IN androstanol_NN (_( Fig_NNP ._.
          1_LS A_DT ,_, 1_CD B_NNP )_) ._. The_DT interaction_NN of_IN SRC-_NNP 3_CD with_IN the_DT preformed_JJ and_CC
          characterized_VBN CAR_NNP /_NN RXR_NNP heterodimer_NN complex_NN was_VBD increased_VBN
          by_IN either_DT TCPOBOP_NNP or_CC 9_CD -_: cis-_NN RA_NNP (_( Fig_NNP ._. 1_LS C_NNP )_) ._. Strikingly_NNP ,_,
          however_RB ,_, coactivator_NN binding_VBG to_TO the_DT heterodimer_NN complex_NN
          was_VBD decreased_VBN below_IN the_DT basal_NN level_NN in_IN the_DT presence_NN of_IN
          both_DT ligands_NNS ._. In_IN addition_NN ,_, SRC-_NNP 3_CD binding_VBG to_TO the_DT
          heterodimer_NN was_VBD decreased_VBN by_IN androstanol_NN and_CC this_DT effect_NN
          was_VBD largely_RB blocked_VBN by_IN 9_CD -_: cis-_NN RA_NNP ._. These_DT effects_NNS of_IN
          9_CD -_: cis-_NN RA_NNP on_IN coactivator_NN binding_VBG to_TO the_DT preformed_JJ
          heterodimer_NN contrast_NN with_IN the_DT strong_JJ stimulatory_NN effect_NN
          observed_VBD with_IN RXR_NNP alone_RB ,_, confirming_VBG the_DT characterization_NN
          of_IN this_DT complex_NN ._. These_DT results_NNS demonstrate_VBP that_IN the_DT
          presence_NN of_IN the_DT RXR_NNP ligand_NN can_MD significantly_RB alter_VB the_DT
          response_NN of_IN the_DT CAR_NNP /_NN RXR_NNP heterodimer_NN to_TO CAR_NNP ligands_NNS ._.
        
        
          Effects_NNPS of_IN rexinoids_NNS on_IN CAR_NNP responses_NNS to_TO agonist_NN
          and_CC inverse_NN agonist_NN ligands_NNS in_IN cells_NNS
          To_TO examine_VB the_DT effects_NNS of_IN RXR_NNP ligands_NNS on_IN CAR_NNP
          transactivation_NN in_IN a_DT more_RBR functional_JJ context_NN ,_, the_DT
          rexinoid_NN LG_NNP 1069_NNP was_VBD combined_VBN with_IN the_DT CAR_NNP inverse_NN agonist_NN
          androstanol_NN and_CC the_DT agonist_NN TCPOBOP_NNP in_IN a_DT series_NN of_IN
          transient_JJ transfection_NN studies_NNS using_VBG different_JJ response_NN
          elements_NNS ._. Initial_JJ studies_NNS were_VBD based_VBN on_IN a_DT well_RB
          characterized_VBN binding_JJ site_NN for_IN CAR_NNP /_NN RXR_NNP heterodimers_NNS ,_, the_DT
          DR-_NNP 5_CD element_NN from_IN the_DT promoter_NN of_IN the_DT retinoic_JJ acid_NN
          receptor_NN β_NN 2_CD isoform_NN [_NN 8_CD 9_CD 16_CD ]_NN ._. In_IN agreement_NN with_IN the_DT
          biochemical_JJ results_NNS ,_, the_DT rexinoid_NN blocked_VBD both_DT the_DT
          stimulatory_NN effect_NN of_IN the_DT agonist_NN and_CC the_DT inhibitory_NN
          effect_NN of_IN the_DT inverse_NN agonist_NN on_IN this_DT element_NN (_( Fig_NNP ._. 2_LS A_DT )_) ._.
          In_IN more_RBR detailed_JJ dose_NN response_NN studies_NNS ,_, 100_CD nM_NN LG_NNP 1069_NNP
          decreased_VBD the_DT inhibitory_NN effect_NN of_IN androstanol_NN by_IN as_RB much_JJ
          as_IN 70_CD %_NN and_CC had_VBD an_DT even_RB stronger_JJR effect_NN on_IN TCPOBOP_NNP
          activation_NN (_( Fig_NNP ._. 2_LS B_NNP )_) ._. Consistent_NNP with_IN previous_JJ results_NNS [_NN
          9_CD ]_NN ,_, deletion_NN of_IN the_DT helix_NN 12_CD AF-_NNP 2_CD motif_NN of_IN CAR_NNP
          eliminated_VBD both_DT constitutive_JJ and_CC ligand_NN dependent_JJ
          transactivation_NN ._. Deletion_NNP of_IN the_DT same_JJ motif_NN in_IN RXR_NNP also_RB
          strongly_RB decreased_VBD transactivation_NN ,_, but_CC did_VBD not_RB
          completely_RB eliminate_VB ligand_NN responses_NNS (_( Fig_NNP ._. 2_LS A_DT )_) ._.
          To_TO test_VB whether_IN the_DT apparent_JJ allosteric_JJ effects_NNS of_IN
          LG_NNP 1069_NNP on_IN CAR_NNP transactivation_NN vary_VBP with_IN different_JJ
          response_NN elements_NNS ,_, the_DT effect_NN of_IN the_DT rexinoid_NN on_IN
          transactivation_NN directed_VBN by_IN cytochrome_NN P_NN 450_CD response_NN
          elements_NNS was_VBD examined_VBN ._. In_IN contrast_NN to_TO the_DT results_NNS with_IN
          the_DT DR-_NNP 5_CD site_NN ,_, but_CC in_IN agreement_NN with_IN the_DT biochemical_JJ
          results_NNS ,_, LG_NNP 1069_NNP alone_RB had_VBD a_DT stimulatory_NN effect_NN on_IN the_DT
          ER-_NNP 6_CD CAR_NNP response_NN element_NN from_IN the_DT promoter_NN of_IN the_DT CYP_NNP 3_CD A_DT 4_CD
          gene_NN (_( Fig_NNP ._. 3_LS )_) ._. This_DT effect_NN was_VBD not_RB due_JJ to_TO RXR_NNP homodimer_NN
          function_NN ,_, since_IN no_DT transactivation_NN was_VBD observed_VBN with_IN RXR_NNP
          alone_RB ._. In_IN contrast_NN to_TO both_DT the_DT DR-_NNP 5_CD and_CC biochemical_JJ
          results_NNS ,_, LG_NNP 1069_NNP did_VBD not_RB block_VB the_DT stimulatory_NN effect_NN of_IN
          TCPOBOP_NNP ._. Instead_RB ,_, the_DT stimulatory_NN effect_NN of_IN the_DT two_CD
          agonists_NNS was_VBD retained_VBN when_WRB they_PRP were_VBD combined_VBN ._. Combining_NNP
          LG_NNP 1069_NNP with_IN the_DT inverse_NN agonist_NN androstanol_NN resulted_VBD in_IN a_DT
          partial_JJ block_NN in_IN its_PRP$ inhibitory_NN effect_NN and_CC an_DT
          intermediate_JJ level_NN of_IN activity_NN ._. Similar_JJ results_NNS were_VBD
          observed_VBN with_IN the_DT tandem_JJ DR-_NNP 4_CD sites_NNS from_IN the_DT CYP_NNP 2_CD B_NNP 10_CD
          gene_NN ,_, except_IN that_DT LG_NNP 1069_NNP did_VBD not_RB have_VB a_DT significant_JJ
          stimulatory_NN effect_NN on_IN its_PRP$ own_JJ ,_, but_CC did_VBD augment_VB the_DT effect_NN
          of_IN TCPOBOP_NNP ._. It_PRP is_VBZ interesting_JJ that_IN these_DT two_CD CYP_NNP elements_NNS
          respond_VBP somewhat_RB differently_RB to_TO RXR_NNP cotransfection_NN ,_, which_WDT
          increases_VBZ responses_NNS directed_VBN by_IN the_DT CYP_NNP 3_CD A_DT 4_CD element_NN but_CC
          modestly_RB decreases_VBZ responses_NNS of_IN the_DT CYP_NNP 2_CD B_NNP 10_CD element_NN (_( data_NNS
          not_RB shown_VBN )_) ._. On_IN both_DT elements_NNS ,_, similar_JJ results_NNS were_VBD
          observed_VBN when_WRB 9_CD -_: cis_NNS RA_NNP was_VBD substituted_VBN for_IN LG_NNP 1069_NNP (_( data_NNS
          not_RB shown_VBN )_) ._. These_DT results_NNS show_VBP that_IN the_DT negative_JJ effects_NNS
          of_IN rexinoids_NNS on_IN TCPOBOP_NNP and_CC androstanol_NN signaling_VBG
          observed_VBN with_IN the_DT DR-_NNP 5_CD site_NN from_IN the_DT RARβ_NNP promoter_NN are_VBP
          not_RB observed_VBN with_IN the_DT DR-_NNP 4_CD and_CC ER-_NNP 6_CD sites_NNS from_IN the_DT CYP_NNP
          promoters_NNS ._. Thus_RB ,_, the_DT CAR_NNP /_NN RXR_NNP heterodimer_NN responds_VBZ
          differently_RB to_TO retinoids_NNS on_IN different_JJ elements_NNS ._.
        
        
          Rexinoid_NNP inhibition_NN of_IN agonist_NN activation_NN of_IN an_DT
          endogenous_JJ CAR_NNP target_NN gene_NN
          A_DT previously_RB described_VBN HepG_NNP 2_CD derivative_JJ stably_RB
          expressing_VBG mouse_NN CAR_NNP [_NN 16_CD ]_NN was_VBD used_VBN to_TO determine_VB the_DT
          effects_NNS of_IN RXR_NNP agonists_NNS on_IN CAR_NNP function_NN in_IN the_DT context_NN of_IN
          native_JJ chromatin_NN ._. Expression_NNP of_IN CYP_NNP 2_CD B_NNP 6_CD ,_, a_DT human_JJ relative_NN
          of_IN CYP_NNP 2_CD B_NNP 10_CD ,_, is_VBZ constitutively_RB induced_VBN in_IN this_DT cell_NN line_NN ._.
          In_IN contrast_NN to_TO the_DT results_NNS with_IN the_DT transient_JJ
          transfections_NNS with_IN the_DT CYP_NNP response_NN elements_NNS ,_, CYP_NNP 2_CD B_NNP 6_CD
          expression_NN was_VBD decreased_VBN to_TO a_DT comparable_JJ extent_NN by_IN
          androstanol_NN ,_, LG_NNP 1069_NNP ,_, and_CC the_DT combination_NN of_IN both_DT ligands_NNS ._.
          CYP_NNP 2_CD B_NNP 6_CD expression_NN was_VBD increased_VBN by_IN TCPOBOP_NNP ,_, as_IN expected_VBN ,_,
          and_CC this_DT response_NN was_VBD blocked_VBN by_IN LG_NNP 1069_NNP treatment_NN ._.
        
      
      
        Discussion_NNP
        A_DT number_NN of_IN RXR_NNP heterodimer_NN complexes_NNS have_VBP been_VBN
        categorized_VBN as_IN either_DT permissive_JJ or_CC non-permissive_JJ based_VBN on_IN
        their_PRP$ responses_NNS to_TO RXR_NNP ligands_NNS [_NN 1_CD ]_NN ._. Although_IN there_EX are_VBP
        some_DT reported_VBN discrepancies_NNS ,_, the_DT PPAR_NNP ,_, FXR_NNP and_CC NGF-IB_NNP /_NN NURR_NNP 1_CD
        complexes_NNS are_VBP generally_RB considered_VBN permissive_JJ ,_, while_IN the_DT
        non-permissive_JJ group_NN includes_VBZ the_DT RAR_NNP ,_, TR_NNP and_CC VDR_NNP complexes_NNS
        (_( see_VB [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN )_) ._. In_IN the_DT permissive_JJ complexes_NNS ,_,
        coactivators_NNS can_MD presumably_RB bind_NN to_TO the_DT AF-_NNP 2_CD surface_NN of_IN
        both_DT partners_NNS and_CC binding_VBG to_TO the_DT RXR_NNP partner_NN is_VBZ stimulated_VBN
        by_IN rexinoid_NN agonists_NNS ._. This_DT can_MD result_VB in_IN distinct_JJ responses_NNS
        depending_VBG on_IN which_WDT of_IN the_DT two_CD partners_NNS is_VBZ activated_VBN ._. In_IN the_DT
        case_NN of_IN the_DT PPARγ_NNP /_NN RXR_NNP complex_NN ,_, for_IN example_NN ,_, activation_NN with_IN
        PPAR_NNP or_CC RXR_NNP specific_JJ ligands_NNS results_NNS in_IN recruitment_NN of_IN
        quite_RB different_JJ coactivators_NNS [_NN 19_CD ]_NN ._.
        Among_IN the_DT non-permissive_JJ complexes_NNS ,_, the_DT RAR_NNP /_NN RXR_NNP
        heterodimer_NN is_VBZ the_DT best_RBS studied_VBN ._. Recent_JJ results_NNS suggest_VBP
        that_IN the_DT C-_NNP terminal_NN helix_NN 12_CD of_IN RXR_NNP exerts_NNS allosteric_JJ
        effects_NNS on_IN RAR_NNP function_NN [_NN 6_CD ]_NN ._. However_RB ,_, additional_JJ studies_NNS
        suggest_VBP that_DT corepressor_NN binding_VBG to_TO the_DT apo-_NN RAR_NNP component_NN
        of_IN the_DT heterodimer_NN blocks_NNS rexinoid_NN induced_VBD binding_JJ of_IN
        coactivators_NNS to_TO RXR_NNP [_NN 7_CD ]_NN ._. These_DT results_NNS suggest_VBP that_IN the_DT
        mechanisms_NNS that_WDT account_NN for_IN the_DT lack_NN of_IN responsiveness_NNS of_IN
        the_DT non-permissive_JJ complexes_NNS are_VBP complex_JJ ._.
        As_IN summarized_VBD in_IN Fig_NNP ._. 5_LS ,_, the_DT results_NNS described_VBD here_RB
        demonstrate_VB that_IN the_DT effects_NNS of_IN RXR_NNP agonists_NNS on_IN the_DT CAR_NNP /_NN RXR_NNP
        heterodimer_NN can_MD be_VB quite_RB different_JJ in_IN different_JJ contexts_NNS ._. 
        In_IN vitro_NN studies_NNS in_IN the_DT absence_NN of_IN
        DNA_NNP demonstrate_VB that_IN CAR_NNP /_NN RXR_NNP heterodimers_NNS can_MD be_VB activated_VBN
        by_IN an_DT agonist_NN ligand_NN for_IN either_DT receptor_NN ._. This_DT positive_JJ
        response_NN to_TO 9_CD -_: cis-_NN RA_NNP contrasts_VBZ with_IN the_DT inhibition_NN that_WDT
        would_MD result_VB from_IN the_DT loss_NN of_IN RXR_NNP to_TO ligand-dependent_JJ
        homodimers_NNS [_NN 20_CD ]_NN ,_, confirming_VBG that_IN these_DT studies_NNS reflect_VBP
        the_DT activity_NN of_IN CAR_NNP /_NN RXR_NNP heterodimers_NNS and_CC demonstrating_VBG that_IN
        such_JJ complexes_NNS can_MD be_VB permissive_JJ for_IN RXR_NNP signaling_VBG ._.
        Remarkably_NNP ,_, however_RB ,_, coactivator_NN binding_JJ is_VBZ decreased_VBN in_IN
        the_DT presence_NN of_IN both_DT of_IN the_DT activating_VBG ligands_NNS ._. Similarly_RB ,_,
        the_DT inhibitory_NN effect_NN of_IN the_DT inverse_NN agonist_NN ligand_NN
        androstanol_NN on_IN coactivator_NN recruitment_NN is_VBZ blocked_VBN by_IN
        9_CD -_: cis-_NN RA_NNP ._.
        In_IN transient_JJ transfections_NNS ,_, the_DT rexinoid_NN LG_NNP 1069_NNP shows_VBZ
        different_JJ effects_NNS on_IN the_DT ability_NN of_IN the_DT xenobiotic_JJ receptor_NN
        to_TO transactivate_NN various_JJ response_NN elements_NNS ._. The_DT rexinoid_NN
        alone_RB has_VBZ no_DT effect_NN on_IN transactivation_NN of_IN the_DT βRARE_NN ,_, but_CC
        strongly_RB inhibits_NNS responses_NNS to_TO both_DT the_DT agonist_NN TCPOBOP_NNP and_CC
        the_DT inverse_NN agonist_NN androstanol_NN ._. In_IN contrast_NN ,_, LG_NNP 1069_NNP can_MD
        stimulate_VB transactivation_NN of_IN the_DT response_NN element_NN from_IN the_DT
        CYP_NNP 3_CD A_DT 4_CD promoter_NN ._. On_IN that_DT element_NN it_PRP does_VBZ not_RB block_VB the_DT
        stimulatory_NN effect_NN of_IN TCPOBOP_NNP ,_, but_CC decreases_VBZ the_DT inhibitory_NN
        effect_NN of_IN the_DT androstanol_NN somewhat_RB ._. On_IN the_DT tandem_JJ CYP_NNP 2_CD B_NNP 10_CD
        elements_NNS ,_, LG_NNP 1069_NNP does_VBZ not_RB have_VB a_DT stimulatory_NN effect_NN on_IN its_PRP$
        own_JJ and_CC does_VBZ not_RB decrease_VB the_DT inhibitory_NN effect_NN of_IN
        androstanol_NN ,_, but_CC it_PRP does_VBZ increase_NN response_NN to_TO TCPOBOP_NNP ._.
        Finally_RB ,_, expression_NN of_IN the_DT endogenous_JJ CYP_NNP 2_CD B_NNP 6_CD gene_NN in_IN CAR_NNP
        expressing_VBG HepG_NNP 2_CD cells_NNS is_VBZ modestly_RB inhibited_VBD by_IN LG_NNP 1069_NNP
        alone_RB ,_, androstanol_NN alone_RB and_CC the_DT combination_NN of_IN both_DT ._. In_IN
        this_DT context_NN ,_, the_DT rexinoid_NN blocks_NNS activation_NN by_IN the_DT agonist_NN
        TCPOBOP_NNP ._.
        These_DT rexinoid_NN responses_NNS share_VBP the_DT general_JJ theme_NN of_IN
        inhibition_NN of_IN some_DT of_IN the_DT effects_NNS of_IN CAR_NNP ligands_NNS by_IN RXR_NNP
        ligands_NNS ,_, but_CC are_VBP clearly_RB quite_RB disparate_JJ ._. The_DT differences_NNS
        may_MD be_VB based_VBN on_IN variations_NNS in_IN experimental_JJ approach_NN or_CC on_IN
        more_RBR fundamental_JJ functional_JJ differences_NNS ._. For_IN example_NN ,_, it_PRP is_VBZ
        possible_JJ that_IN the_DT inhibitory_NN effect_NN of_IN LG_NNP 1069_NNP in_IN the_DT stable_JJ
        CAR_NNP expressing_VBG cell_NN line_NN is_VBZ based_VBN on_IN the_DT sequestration_NN of_IN
        limiting_VBG amounts_NNS of_IN RXR_NNP into_IN ligand-dependent_JJ homodimers_NNS ,_,
        as_IN has_VBZ been_VBN suggested_VBN in_IN previous_JJ studies_NNS using_VBG primary_JJ
        hepatocytes_NNS [_NN 17_CD ]_NN ._. However_RB ,_, similar_JJ effects_NNS were_VBD observed_VBN
        with_IN the_DT relatively_RB large_JJ amounts_NNS of_IN RXR_NNP used_VBD for_IN the_DT
        biochemical_JJ studies_NNS or_CC with_IN the_DT transient_JJ transfections_NNS ,_,
        which_WDT relied_VBD on_IN cotransfected_JJ RXR_NNP ._. It_PRP is_VBZ also_RB possible_JJ that_IN
        differences_NNS in_IN the_DT chromatin_NN context_NN could_MD contribute_VB to_TO
        the_DT differences_NNS between_IN the_DT effects_NNS observed_VBD with_IN the_DT
        endogenous_JJ and_CC transiently_RB transfected_JJ promoters_NNS ._. However_RB ,_,
        such_JJ differences_NNS cannot_NN account_NN for_IN the_DT results_NNS with_IN
        reporter_NN plasmids_NNS that_WDT differ_VBP only_RB in_IN the_DT identity_NN of_IN the_DT
        response_NN element_NN ._. Overall_RB ,_, we_PRP conclude_VBP that_IN binding_VBG of_IN both_DT
        the_DT DNA_NNP and_CC the_DT RXR_NNP ligands_NNS can_MD result_VB in_IN allosteric_JJ
        effects_NNS on_IN the_DT function_NN of_IN the_DT CAR_NNP /_NN RXR_NNP heterodimer_NN ._.
        The_DT disparities_NNS in_IN these_DT responses_NNS preclude_VB a_DT single_JJ ,_,
        simple_JJ explanation_NN for_IN the_DT effects_NNS of_IN rexinoids_NNS on_IN CAR_NNP /_NN RXR_NNP
        heterodimers_NNS ._. Nonetheless_RB ,_, one_CD attractive_JJ possibility_NN is_VBZ
        that_IN binding_VBG of_IN the_DT RXR_NNP agonist_NN exerts_NNS direct_JJ inhibitory_NN
        effects_NNS on_IN either_DT the_DT binding_JJ or_CC functional_JJ effects_NNS of_IN the_DT
        CAR_NNP ligands_NNS ._. Some_DT precedence_NN for_IN a_DT significant_JJ allosteric_JJ
        effect_NN of_IN one_CD heterodimer_NN partner_NN on_IN another_DT is_VBZ provided_VBN by_IN
        the_DT inability_NN of_IN the_DT insect_NN ecdysone_NN receptor_NN to_TO bind_NN its_PRP$
        steroid_NN ligand_NN in_IN the_DT absence_NN of_IN its_PRP$ heterodimer_NN partner_NN
        USP_NNP [_NN 21_CD ]_NN ._.
        The_DT outcome_NN of_IN this_DT inhibition_NN of_IN CAR_NNP ligand_NN binding_JJ
        would_MD be_VB somewhat_RB different_JJ depending_VBG on_IN whether_IN or_CC not_RB the_DT
        RXR_NNP agonist_NN was_VBD able_JJ to_TO activate_VBP the_DT basal_NN transactivation_NN
        of_IN CAR_NNP /_NN RXR_NNP heterodimer_NN bound_VBN to_TO a_DT particular_JJ element_NN ._. On_IN
        the_DT βRARE_NN ,_, for_IN example_NN ,_, the_DT RXR_NNP agonist_NN might_MD bind_NN ,_, but_CC not_RB
        increase_VB transactivation_NN beyond_IN that_DT observed_VBD in_IN the_DT
        absence_NN of_IN ligands_NNS ._. In_IN this_DT case_NN ,_, blocking_VBG TCPOBOP_NNP binding_JJ
        would_MD strongly_RB inhibit_VB TCPOBOP-dependent_NNP transactivation_NN ._.
        In_IN the_DT case_NN of_IN the_DT CYP_NNP 3_CD A_DT 4_CD response_NN element_NN ,_, however_RB ,_,
        activation_NN by_IN the_DT RXR_NNP agonist_NN is_VBZ comparable_JJ to_TO that_DT
        observed_VBD with_IN TCPOBOP_NNP alone_RB ._. Thus_RB ,_, blocking_VBG TCPOBOP_NNP binding_JJ
        would_MD not_RB result_VB in_IN the_DT net_JJ inhibitory_NN effect_NN observed_VBD with_IN
        the_DT βRARE_NN ,_, but_CC could_MD account_VB for_IN the_DT lack_NN of_IN additive_JJ
        effect_NN of_IN the_DT two_CD ligands_NNS ._.
        A_DT variety_NN of_IN factors_NNS complicate_VB this_DT relatively_RB simple_JJ
        model_NN ,_, including_VBG the_DT specific_JJ cytoplasmic_JJ to_TO nuclear_JJ
        translocation_NN that_WDT is_VBZ required_VBN for_IN CAR_NNP transactivation_NN in_IN
        the_DT liver_NN [_NN 22_CD 23_CD ]_NN ._. Rexinoids_NNP by_IN themselves_PRP are_VBP
        apparently_RB unable_JJ to_TO induce_VB this_DT translocation_NN process_NN in_IN
        rat_NN [_NN 17_CD ]_NN or_CC mouse_NN (_( data_NNS not_RB shown_VBN )_) hepatocytes_NNS and_CC thus_RB
        cannot_NN directly_RB activate_VBP CAR_NNP targets_NNS ._. More_RBR complex_JJ
        combinatorial_NN effects_NNS of_IN other_JJ coactivators_NNS or_CC corepressors_NNS
        (_( e_SYM ._. g_SYM ._. [_NN 6_CD 7_CD ]_NN )_) could_MD also_RB contribute_VB to_TO the_DT observed_VBD
        responses_NNS ._. Recent_JJ results_NNS suggest_VBP that_IN CAR_NNP can_MD interact_NN
        with_IN NCoR_NNP or_CC SMRT_NNP in_IN the_DT presence_NN of_IN inverse_NN agonists_NNS [_NN 24_CD
        ]_NN ,_, although_IN such_JJ interactions_NNS appear_VBP much_RB weaker_JJR than_IN
        those_DT of_IN other_JJ receptors_NNS ._. Further_RB characterization_NN of_IN
        potential_JJ CAR_NNP cofactors_NNS ,_, as_RB well_RB as_IN the_DT development_NN of_IN
        sensitive_JJ and_CC direct_JJ ligand_NN binding_JJ assays_NNS will_MD be_VB required_VBN
        to_TO define_VB the_DT molecular_JJ mechanisms_NNS that_WDT account_NN for_IN the_DT
        diverse_JJ effects_NNS of_IN rexinoids_NNS on_IN CAR_NNP transactivation_NN ._.
      
      
        Conclusions_NNP
        Overall_RB ,_, we_PRP conclude_VBP that_IN the_DT disparate_JJ effects_NNS of_IN
        rexinoids_NNS on_IN CAR_NNP /_NN RXR_NNP heterodimers_NNS in_IN different_JJ contexts_NNS add_VBP
        significantly_RB to_TO the_DT potential_JJ complexity_NN of_IN the_DT effects_NNS of_IN
        RXR_NNP ligands_NNS on_IN such_JJ nuclear_JJ receptor_NN heterodimers_NNS ,_, and_CC
        demonstrate_VB that_IN classifying_VBG a_DT particular_JJ complex_NN as_IN
        permissive_JJ or_CC non-permissive_JJ can_MD be_VB an_DT oversimplification_NN ._.
        The_DT results_NNS described_VBD here_RB also_RB suggest_VBP that_IN rexinoids_NNS may_MD
        have_VB modulatory_NN effects_NNS on_IN xenobiotic_JJ responses_NNS ,_, and_CC that_IN
        such_JJ effects_NNS may_MD differ_VB for_IN different_JJ CAR_NNP /_NN RXR_NNP target_NN genes_NNS ._.
        A_DT systematic_JJ examination_NN of_IN the_DT effects_NNS of_IN RXR_NNP ligands_NNS and_CC
        retinoid_NN status_NN on_IN a_DT number_NN of_IN the_DT growing_VBG set_NN of_IN CAR_NNP
        target_NN genes_NNS will_MD be_VB required_VBN to_TO explore_VB this_DT
        possibility_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Surface_NNP plasmon_NN resonance_NN
          The_DT effect_NN of_IN ligands_NNS on_IN coactivator_NN binding_JJ was_VBD
          evaluated_VBN using_VBG the_DT BIAcore_NNP instrument_NN as_IN described_VBN [_NN 25_CD
          26_CD ]_NN ._. For_IN interaction_NN of_IN CAR_NNP ,_, RXR_NNP and_CC CAR_NNP /_NN RXR_NNP
          heterodimer_NN with_IN SRC-_NNP 3_CD ,_, a_DT GST-SRC-_NNP 3_CD fusion_NN protein_NN
          containing_VBG the_DT receptor_NN interaction_NN domain_NN of_IN the_DT
          coactivator_NN was_VBD expressed_VBN in_IN bacteria_NNS and_CC purified_JJ ._. This_DT
          fusion_NN protein_NN was_VBD immobilized_JJ in_IN flow_NN cells_NNS using_VBG
          anti-_NN GST_NNP antibody_NN ._. Lack_NN of_IN binding_JJ of_IN free_JJ GST_NNP
          demonstrated_VBD that_IN the_DT surface_NN was_VBD saturated_VBN with_IN
          GST-SRC_NNP 3_CD ._. Purified_NNP CAR_NNP and_CC RXR_NNP proteins_NNS were_VBD produced_VBN in_IN
          bacteria_NNS and_CC preincubated_JJ overnight_JJ at_IN 4_CD °_NN C_NNP alone_RB or_CC in_IN
          combination_NN ,_, and_CC in_IN the_DT presence_NN or_CC absence_NN of_IN 10_CD -_: 5_CD M_NNP
          androstanol_NN ,_, 10_CD -_: 6_CD M_NNP TCPOBOP_NNP ,_, 10_CD -_: 6_CD M_NNP of_IN 9_CD cis-_NN RA_NNP ,_, as_IN
          appropriate_JJ ._. CAR_NNP alone_RB ,_, RXR_NNP alone_RB ,_, and_CC CAR_NNP /_NN RXR_NNP
          heterodimers_NNS bound_VBN to_TO various_JJ ligands_NNS were_VBD injected_VBN
          individually_RB into_IN flow_NN cells_NNS and_CC binding_JJ was_VBD measured_VBN as_IN
          described_VBN [_NN 25_CD 26_CD ]_NN ._.
        
        
          Plasmids_NNP
          The_DT βRARE-TK-Luc_JJ reporter_NN plasmid_NN with_IN three_CD copies_NNS of_IN
          the_DT DR-_NNP 5_CD motif_NN from_IN the_DT promoter_NN of_IN the_DT mouse_NN RARβ_NNP 2_CD gene_NN
          has_VBZ been_VBN described_VBN previously_RB ,_, as_IN has_VBZ the_DT CYP_NNP 2_CD B_NNP 10_CD -_: TK-Luc_NNP
          reporter_NN with_IN two_CD copies_NNS of_IN the_DT DR-_NNP 4_CD type_NN elements_NNS from_IN
          the_DT promoter_NN of_IN the_DT mouse_NN CYP_NNP 2_CD B_NNP 10_CD gene_NN and_CC the_DT
          CYP_NNP 3_CD A_DT 4_CD -_: TK-luc_NNP reporter_NN with_IN three_CD copies_NNS of_IN the_DT ER-_NNP 6_CD
          element_NN from_IN the_DT human_JJ CYP_NNP 3_CD A_DT 4_CD promoter_NN [_NN 16_CD ]_NN ._.
          Expression_NNP vectors_NNS for_IN full_JJ length_NN mCAR_NN and_CC RXR_NNP proteins_NNS
          were_VBD as_IN described_VBN [_NN 9_CD ]_NN ._. The_DT cdm_NN 8_CD -_: mCARΔ_NN 8_CD deletion_NN
          construct_VB containing_VBG a_DT deletion_NN of_IN the_DT last_JJ 8_CD amino_JJ acids_NNS
          and_CC the_DT mutant_JJ with_IN 2_CD helix_NN 3_CD mutations_NNS (_( F_NN 171_CD L_NNP ,_, I_PRP 174_CD A_DT )_)
          that_WDT block_VBP ligand_NN binding_JJ and_CC response_NN have_VBP been_VBN
          described_VBN previously_RB [_NN 16_CD ]_NN ,_, as_IN has_VBZ the_DT cdm_NN 8_CD -_: RXRΔ_NNP 19_CD
          construct_VB with_IN a_DT deletion_NN of_IN the_DT last_JJ 19_CD amino_JJ acids_NNS [_NN 3_CD
          ]_NN ._.
        
        
          Cell_NNP culture_NN and_CC transfections_NNS
          HepG_NNP 2_CD cells_NNS were_VBD maintained_VBN in_IN Dulbecco_NNP 's_POS modified_VBN
          Eagle_NNP medium_NN (_( DMEM_NNP )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ bovine_JJ
          serum_NN (_( Hyclone_NNP )_) ._. For_IN transfections_NNS ,_, 10_CD 5_CD HepG_NNP 2_CD cells_NNS were_VBD
          plated_JJ in_IN 24_CD well_RB dishes_NNS with_IN DMEM_NNP supplemented_JJ with_IN 10_CD %_NN
          charcoal_NN stripped_VBD serum_NN and_CC transfected_JJ using_VBG the_DT calcium_NN
          phosphate_NN precipitation_NN method_NN as_IN described_VBN [_NN 16_CD ]_NN ._. The_DT
          next_JJ morning_NN ,_, cells_NNS were_VBD washed_VBN with_IN phosphate_NN buffered_JJ
          saline_NN and_CC ligands_NNS were_VBD added_VBN ._. Typically_RB ,_, transfections_NNS
          included_VBD 100_CD -_: 200_CD ng_NN of_IN luciferase_NN reporter_NN plasmids_NNS ,_, 100_CD
          ng_NN of_IN β-galactosidase_JJ (_( β-gal_JJ )_) internal_JJ control_NN plasmid_NN
          (_( CMV_NNP β-_NN Gal_NNP )_) ,_, and_CC 100_CD ng_NN of_IN cdm_NN 8_CD expression_NN vectors_NNS ._. A_DT
          total_NN of_IN 500_CD ng_NN of_IN plasmids_NNS was_VBD used_VBN per_IN well_RB ._. Cells_NNP were_VBD
          assayed_JJ for_IN luciferase_NN (_( Promega_NNP )_) activities_NNS 24_CD hours_NNS
          after_IN addition_NN of_IN ligands_NNS and_CC reporter_NN expression_NN was_VBD
          normalized_JJ to_TO β-galactosidase_JJ activity_NN (_( Tropix_NNP )_) according_VBG
          to_TO the_DT manufacturer_NN 's_POS directions_NNS ._. Similar_JJ results_NNS were_VBD
          obtained_VBN from_IN at_IN least_JJS three_CD independent_JJ experiments_NNS ._.
          Error_NNP bars_NNS are_VBP included_VBN for_IN experiments_NNS where_WRB variations_NNS
          were_VBD more_JJR than_IN 10_CD %_NN ._. A_DT previously_RB described_VBN derivative_NN of_IN
          HepG_NNP 2_CD cells_NNS stably_RB expressing_VBG mCAR_NN [_NN 16_CD ]_NN was_VBD used_VBN for_IN
          RNA_NNP analysis_NN ._. Cells_NNP were_VBD subcultured_JJ and_CC incubated_JJ in_IN
          DMEM_NNP supplemented_JJ with_IN 10_CD %_NN charcoal_NN stripped_VBD bovine_JJ serum_NN
          overnight_JJ ._. Various_JJ ligands_NNS were_VBD added_VBN and_CC total_JJ RNA_NNP was_VBD
          prepared_VBN 9_CD hours_NNS later_RB and_CC used_VBN for_IN Northern_NNP blotting_VBG
          using_VBG standard_JJ procedures_NNS [_NN 27_CD ]_NN ._.
        
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Authors_NNP '_'' contributions_NNS
        I_PRP ._. T_NN ._. and_CC S_NNP ._. S_NNP ._. C_NNP ._. carried_VBD out_RP the_DT studies_NNS of_IN CAR_NNP
        function_NN in_IN transiently_RB transfected_JJ cells_NNS ._. S_NNP ._. S_NNP ._. C_NNP ._. carried_VBD
        out_RP the_DT studies_NNS of_IN gene_NN expression_NN in_IN stable_JJ CAR_NNP expressing_VBG
        cells_NNS ._. B_NNP ._. C_NNP ._. carried_VBD out_RP the_DT surface_NN plasmon_NN resonance_NN
        studies_NNS ._. D_NNP ._. D_NNP ._. M_NNP ._. directed_VBD these_DT studies_NNS ._. All_DT authors_NNS read_VBP
        and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
